
MaxCyte Shares Gain After Announcing Cell Therapy Licensing Deal with Genentech
MaxCyte Inc. stock rose more than 5% after the company revealed a strategic partnership granting Genentech, a member of the Roche Group, access to its cell-engineering platform for therapy development.







